MBRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Moleculin Biotech Inc (MBRX) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks clear positive catalysts, has weak financial performance, and no strong trading signals. While analysts maintain a Buy rating, the significant reduction in price targets and lack of recent news or influential trading activity suggest a cautious approach.
The technical indicators show mixed signals. The MACD is positive and expanding, which is a bullish sign. However, the RSI is neutral at 50.518, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level of 4.394 in pre-market, indicating limited immediate upside potential.
Analysts maintain a Buy rating despite reduced price targets.
Significant reduction in price targets by analysts following a 1-for-25 reverse stock split. Weak financial performance with no revenue growth, negative net income, and declining EPS. No recent news or significant trading activity from hedge funds, insiders, or Congress.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$25.4M (up 139.79% YoY), and a sharp EPS decline to -17.02 (-76.13% YoY). Gross margin remains at 0%.
Analysts maintain a Buy rating but have significantly lowered price targets. Roth Capital reduced the target from $300 to $31, and H.C. Wainwright adjusted it from $4 to $22 following the reverse stock split.
